The glutathione transferase omega 1-1 GSTO1∗A140D polymorphism is associated with unfavourable prognosis in patients with thymoma and myasthenia gravis
Advances in Medical Sciences · 2026-09 · 71 (2) · 241-248
DOI: 10.1016/j.advms.2026.06.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Medical Sciences, 2026-09. Verfasst von Simona Piaggi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Research NTMS, University of Pisa, Pisa, Italy. Die Arbeit nennt 56 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Thymomas are rare organotypic tumors frequently associated with immune-related paraneoplastic syndromes. The genetic alterations of thymomas are largely unknown and rely on general transcription factor I (GTF2I) and Harvey rat sarcoma (HRAS) mutations. Glutathione transferase omega-1-1 (GSTO1-1) is an atypical member of the glutathione transferase superfamily involved in regulating pro-survival and anti-apoptotic pathways. The association between GSTO1-1 polymorphisms and the increased risk of different types of cancer has been investigated, but no study has focused on thymomas to date. Therefore, we have investigated whether two major GSTO1-1 genetic variants, namely GSTO1∗A140D and GSTO1∗E155del polymorphisms, might represent a risk for thymoma development. PATIENTS AND METHODS: Genotyping was performed in 47 patients diagnosed with thymoma and myasthenia gravis by using a PCR-RFLP assay. RESULTS: The results of our study show no significant correlation between the two polymorphisms and thymoma histotype, stage, disease progression, and myasthenia gravis symptoms. A worse progression-free survival (PFS; 66.8 vs 236.6 months) was found, however, in patients bearing the homozygous GSTO1∗A140D polymorphism, suggesting a potential role for GSTO1-1 in thymoma. Indeed, enzymes with a regulatory function, such as GSTO1-1, could produce very different effects depending on both their activity and the relevance of their substrates in the risk/progression of a specific neoplasm. CONCLUSIONS: GSTO1∗A140D polymorphism deserves to be further explored as a possible risk factor associated with a worse PFS in thymoma. Specific targets of GSTO1-1 in thymomas need to be determined.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Translational Research NTMS, University of Pisa, Pisa, Italy.
- Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.
- Department of Translational Research NTMS, University of Pisa, Pisa, Italy. Electronic address: alessandro.corti@unipi.it.
Zitieren
APA
Piaggi, S., Carnicelli, V., Pardini, E., Aprile, V., Coppedè, F., Pompella, A., Petrini, I., & Corti, A. (2026). The glutathione transferase omega 1-1 GSTO1∗A140D polymorphism is associated with unfavourable prognosis in patients with thymoma and myasthenia gravis. Advances in Medical Sciences, 71(2), 241-248. https://doi.org/10.1016/j.advms.2026.06.003
Vancouver
Piaggi S, Carnicelli V, Pardini E, Aprile V, Coppedè F, Pompella A, et al. The glutathione transferase omega 1-1 GSTO1∗A140D polymorphism is associated with unfavourable prognosis in patients with thymoma and myasthenia gravis. Advances in Medical Sciences. 2026;71(2):241-248. doi:10.1016/j.advms.2026.06.003
BibTeX
@article{Piaggi2026,
author = {Piaggi, Simona and Carnicelli, Vittoria and Pardini, Eleonora and Aprile, Vittorio and Coppedè, Fabio and Pompella, Alfonso and Petrini, Iacopo and Corti, Alessandro},
title = {The glutathione transferase omega 1-1 GSTO1∗A140D polymorphism is associated with unfavourable prognosis in patients with thymoma and myasthenia gravis},
journal = {Advances in Medical Sciences},
year = {2026},
volume = {71},
number = {2},
pages = {241--248},
doi = {10.1016/j.advms.2026.06.003}
}
EUVIMED